**HMG-CoA Reductase Inhibitors Reduce MMP-9 Secretion by Macrophages**


**Abstract**—Macrophages secrete matrix metalloproteinases (MMPs) that may weaken the fibrous cap of atherosclerotic plaque, predisposing its fissuration. The 92-kDa gelatinase B (MMP-9) has been identified in abdominal aortic aneurysms and in atherosclerotic tissues. Fluvastatin, through the inhibition of the isoprenoid pathway, inhibits major processes of atherogenesis in experimental models (smooth muscle cell migration and proliferation and cholesterol accumulation in macropages). We studied the effect of fluvastatin on the activity of MMP-9 in mouse and human macrophages in culture. Conditioned media of cells treated for 24 hours with fluvastatin were analyzed by gelatin zymography. In mouse macrophages, fluvastatin (5 to 100 μmol/L) significantly inhibited in a dose-dependent manner MMP-9 activity from 20% to 40% versus control. The drug, at a concentration as low as 5 μmol/L, inhibited MMP-9 activity (~30%) in human monocyte-derived macrophages as well. Phorbol esters (TPA, 50 ng/mL) stimulated MMP-9 activity by 50%, and fluvastatin inhibited this enhanced activity up to 50% in both mouse and human macrophages. The above results on the secretion of MMP-9 were confirmed by Western blotting and ELISA. The inhibitory effect of fluvastatin was overcome by the simultaneous addition of exogenous mevalonate (100 μmol/L), a precursor of isoprenoids. Fluvastatin’s effect was fully reversible, and the drug did not cause any cellular toxicity. The statin did not block directly the in vitro activation of the secreted protease. Similar data were obtained with simvastatin. Altogether, our data indicate an inhibition of MMP-9 secretion by the drug. This effect is mediated by the inhibition of synthesis of mevalonate, a precursor of numerous derivatives essential for several cellular functions.

**Key Words:** statins ■ macrophages ■ plaque stability ■ metalloproteinases

**A** dvanced human atherosclerotic plaques are characterized by a lipid core covered by a fibrous cap composed of smooth muscle cells (SMCs) and extracellular matrix.1 These lesions also have chronic inflammatory infiltrates of macrophages and T lymphocytes. Composition and stability of the plaque, rather than its volume (ie, severity of stenosis), are the most important determinants of atherosclerosis complications. Plaque disruption with superimposed thrombosis is the main cause for the acute coronary syndrome of unstable angina, myocardial infarction, and sudden death.2 Plaque instability, manifesting as ulceration of the fibrous cap, plaque rupture, or intraplaque hemorrhage, is characteristic of plaques with a high lipid content and excess macrophages in the cap.3,4

Disrupted aortic caps contain fewer SMCs (collagen-synthesizing cells) and less collagen than intact caps.5 Collagen is the main component of fibrous caps responsible for their tensile strength.6 In addition to the plaque rupture, the matrix composition participates in several key events in the development of the atherosclerotic lesion: cell migration and proliferation, lipoprotein retention, cell adhesion, calcification, thrombosis, coagulation, and apoptosis.6 A wide range of proteases may be produced at focal sites in plaques. Macrophages are capable of degrading extracellular matrix by phagocytosis or by secreting proteolytic enzymes, in particular a family of metalloproteinases (MMPs) that may weaken the fibrous cap, predisposing its rupture.7 The 92-kDa gelatinase B, or MMP-9, is the most prevalent form, expressed by virtually all activated macrophages, and has been shown to be more common in atherectomy materials from unstable angina8 and abdominal aortic aneurysm.9 In addition to macrophages, SMCs may release MMPs, an event relevant not only to atherogenesis but especially to the process of restenosis after angioplasty.7 MMPs play a major role in restenosis by liberating the SMC from its pericellular matrix cage as a prerequisite to proliferation and migration.10-14 MMPs are a family of Zn(2+) - and Ca(2+) -dependent enzymes, which are important in the resorption of extracellular matrixes in both physiological and pathological processes. The MMPs are secreted as the proenzyme and, once activated, can completely degrade all extracellular matrix components. The regulation of these enzymes is very important and occurs at 3
interleukin-1, platelet-derived growth factor, and tumor necrosis factor-α stimulate the synthesis of MMPs; transforming growth factor-β (TGF-β), heparin, and corticosteroids have an inhibitory effect.7,15 Plasmin is a potent proenzyme activator of most MMPs, but plasmin-independent pathways also exist.17,18 In vitro experiments have shown that phorbol esters (12-0-tetradecanoylphorbol 13-acetate (TPA)) and lipopolysaccharide can stimulate MMP secretion.19 MMPs are inhibited by a family of naturally occurring specific inhibitors (tissue inhibitors of metalloproteinases [TIMPs]), which are secreted multifunctional proteins essential in the regulation of connective tissue metabolism.

In addition to lipid-lowering therapy, which most probably affects the size of the atheromatous core, plaque stabilization could be achieved by a direct inhibition of MMPs in the arterial wall. Along with TGF-β, corticosteroids, and heparin, several synthetic inhibitors have been investigated: namely, tetracyclines, antracyclines, and synthetic peptides. The efficacy of these molecules in therapy, however, is questionable.7 The inhibition of MMP activity also has been investigated in tumor therapy.

In our laboratory, we demonstrated that fluvastatin, a hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin), may directly interfere with the major processes of atherosogenesis occurring in the arterial wall.20 SMC migration and proliferation are inhibited by the drug,21,22 and cholesterol accumulation is prevented in macrophages by reducing modified-LDL endocytosis.24 Interestingly, the inhibitory activity observed in macrophages was more pronounced in cholesterol-loaded cells than in normal cells, suggesting a potential selectivity of the drug for the foam cells and hence for the atherosclerotic lesion.24 All cellular effects mentioned above are mediated by inhibition of the isoprenoid pathway. Because the isoprenoid pathway is involved in several cellular processes25 and macrophage-derived foam cells constitutively produce MMPs,26 we studied the effect of fluvastatin on secreted MMP-9 activity in macrophages in vitro.

Methods

Cell Culture

Mouse peritoneal macrophages (MPMs) were collected by peritoneal lavage with PBS from mice given a 3-mL intraperitoneal injection of 4% thioglycollate in water. The MPMs were pelleted, washed twice with serum-free Dulbeco’s modified Eagle’s medium (DMEM; GibCO BRL), plated at a density of 3×10^6 cells/35-mm dish, and allowed to adhere to dishes for 2 hours in DMEM containing 10% FBS. Then, plates were washed 3 times with DMEM to remove nonadherent cells and incubated in DMEM containing 10% FBS until the day of the experiment.

Circulating human monocyte–derived macrophages (HMs) were isolated from the blood of healthy donors. In brief, blood was centrifuged, and theuffy coats were underlayered with Ficoll-Paque (Pharmacia) and centrifuged at 320g for 35 minutes at 25°C. The monocytes in a broad band below the interface were collected using a siliconized Pasteur pipette and washed 3 times with cold PBS. The final pellet was resuspended in serum-free DMEM, and the cells were plated at a density of 3×10^6 cells in a 35-mm dish. After 2 hours, cell monolayers were washed twice, and the adherent cells were incubated for 10 to 14 days with DMEM containing 10% human AB serum and insulin (8 μg/mL).

To generate the conditioned media, cells were incubated for 24 hours at 37°C with DMEM supplemented with 0.2% BSA (Sigma) and increasing concentrations of fluvastatin in the absence or presence of phorbol esters (TPA, 50 ng/mL; Sigma). At the end of the incubation, the conditioned media were collected, and the activity of secreted MMP-9 was analyzed by zymography. Cellular protein content was measured according to Lowry et al.20 Cellular toxicity caused by the drug was assessed using the dimethylthiazol-diphenyltetrazolium bromide assay (MTT), which relied on the ability of viable cells to actively metabolize a tetrazolium dye.27

Western Blot Analysis

Aliquots of the conditioned media (40 μL per lane) were run on 10% polyacrylamide gel containing SDS, under nonreducing conditions. The proteins were blotted to nitrocellulose membranes (Bio-Rad) and incubated with a 3% solution of defatted dried milk in PBS containing 0.1% Tween 20 (PBS-T) to block nonspecific binding. Then a mouse monoclonal antibody anti–human MMP-9 (clone 6-6B; Calbiochem) diluted in PBS-T was added, and the incubation continued for 1 hour. This antibody recognizes both the latent (92 kDa) and active (83 kDa) forms of human MMPs-9 under nonreducing conditions but only the latent form under reducing conditions.28 The bound primary antibody was detected using an antirabbit secondary antibody conjugated to horseradish peroxidase (Sigma) and the enhanced chemiluminescence kit (Amersham) according to the manufacturer’s instructions.

Northern Blot Analysis

RNA was extracted (RNAzol B; Tel-Test Inc) from 3×10^3 to 4×10^3 primary HMs cultured for 12 days and treated with and without 50 μmol/L fluvastatin for 24 hours before harvest. Equal amounts of total RNA (10 μg) were denatured in 2.2 mol/L formaldehyde, 50% deionized formamide, and 50 mmol/L MOPS (pH 7.0) at 55°C and electrophoresed on 1% agarose gels containing 3.4% formaldehyde. RNA was blotted transferred to GeneScreen Plus membranes using 10× SSC and fixed with UV irradiation. Blots were prehybridized at 68°C for 1 hour. An MMP-9 probe was generated from THP-1 cells.
treated with TPA by reverse transcription–polymerase chain reaction (PCR) of total RNA using the following primers: sense, 5′ TGGGCAGATTCCAAACCTTTGAGGGC 3′ and antisense, 5′ CCATTCACGTCGTCCTTATGCAAGGG 3′. The 1003-bp product was subcloned into the pCRII vector, and its sequence was verified as MMP-9. Purified MMP-9 probe (QIAquick, Quiagen, 25 ng) generated by PCR from the vector or a G3PDH probe (Clontech) were labeled with [32P]dCTP by random priming and incubated with the blots in ExpressHyb (Clontech) for 1 hour at 68°C. Blots were washed (2× SSC; 0.05% SDS) exhaustively at room temperature and given a final wash at 50°C (0.1× SSC; 0.1% SDS) for 10 minutes. Blots were exposed for autoradiography (X-OMAT AR, Kodak) and then placed on a Bio-Rad BI screen for quantitative analysis in the Bio-Rad GS 363 Molecular Imager. After autoradiography to detect MMP-9 mRNA, the blot was stripped by incubation in 0.01% SDS, 0.01× SSC for 15 minutes at 100°C. The blot then was reprobed for the G3PDH housekeeping gene.

ELISA

The amount of secreted MMP-9 protein was quantified using the highly specific Biotrak Matrix MMP-9 ELISA systems (Amersham). The MMP-9 assay uses 2 antibodies directed against different epitopes of MMP-9 and does not show detectable cross-reactivity with MMP-1, -2, and -3 and TIMP-1 and -2 (Amersham). Aliquots of conditioned media were analyzed as suggested by the manufacturer.

Statistical Analysis

For quantitation of Western blots and zymograms, densitometric scanning was performed using a system incorporating a video camera and a computer analysis package (NIH Image 1.52 image analysis software). Each experiment was performed at least 3 times with different preparations of cells. Background was set for each gel, and each lane was analyzed sequentially. Results were normalized by cellular protein content and expressed as optical density units. To validate the method, a linear response of optical density units versus dilution was obtained for different serial dilutions on 2 separate samples (data not shown). To standardize conditions between gels, an aliquot of a standard sample was loaded on each gel, and values for each band were normalized to the value of the band of the reference sample run on the same gel. Data are presented as mean±SD and analyzed using the Student t test. P values <0.05 were considered statistically significant.

Results

To study the effect of fluvastatin on MMP-9 activity, we incubated MPMs for 24 hours with increasing concentrations of the drug. The conditioned media were analyzed using gelatin zymography. This technique allows the visualization of both the active and proenzyme forms of gelatinase. In our experimental conditions, we observed only the pro–MMP-9 form (Figure 1). The analysis of the data obtained in 3 different experiments showed that the addition of fluvastatin (5 to 100 μmol/L) significantly inhibited in a dose-dependent manner MMP-9 activity from 20% to 40% versus control (nontreated cells) (Figure 2A). As expected, dexamethasone, a corticosteroid known to inhibit MMP gene transcription,7 suppressed almost completely the enzyme activity (Figure 2A). In the next series of experiments, we stimulated MMP activity by incubating the cells with phorbol ester (TPA, 50 ng/mL), a known enhancer of MMP expression.7 Treatment with TPA increased MMP-9 activity >50%.

Figure 1. Representative gelatin zymography gel showing the effect of fluvastatin on MMP-9 activity in MPMs. Mouse macrophages were incubated for 24 hours with increasing concentrations of fluvastatin. Conditioned media were collected and MMP-9 activity measured by gelatin zymography.

Figure 2. Fluvastatin inhibits MMP-9 activity in MPMs. Cells were incubated for 24 hours with increasing concentrations of fluvastatin in the absence (A) or presence (B) of TPA (50 ng/mL). Data were quantified by densitometric scanning and expressed as the mean±SD of 3 experiments performed in duplicate. Student t test: A, a indicates P < 0.05; b, P < 0.01 vs control (nontreated cells). B, a indicates P < 0.01 vs TPA alone.
and fluvastatin was still effective in inhibiting the enhanced protease activity by almost 50% (Figure 2B).

Our previous data have shown that fluvastatin may directly interfere with the major processes of atherogenesis occurring in the arterial wall through the inhibition of the isoprenoid pathway. Because mevalonate is the precursor of isoprenoid compounds, we postulated that the inhibitory effect of fluvastatin might be due to a deprivation of mevalonate caused by the drug. To test this hypothesis, we incubated the cells with fluvastatin in the presence of exogenous mevalonate (100 μmol/L). As shown in Figure 3, the addition of mevalonate fully overcame the inhibitory effect of the statin, in both the absence and presence of TPA.

To determine whether the inhibitory effect of fluvastatin was due to an interference with the activation process after MMP-9 had been secreted, we incubated MPMs with medium alone or containing fluvastatin (5 μmol/L) or fluvastatin + mevalonate (100 μmol/L) in the absence or presence of TPA (50 ng/mL). Conditioned media were collected and MMP-9 activity measured by gelatin zymography. Data are mean ± SD of 3 experiments performed in duplicate. Student t test: a indicates $P<0.05$ vs control; b, $P<0.05$ vs fluvastatin alone; c, $P<0.05$ vs TPA alone; and d, $P<0.05$ vs TPA + fluvastatin.

![Figure 3](http://atvb.ahajournals.org/)

Figure 3. Mevalonate prevents the inhibitory effect of fluvastatin on MMP-9 activity in MPMs. Mouse macrophages were incubated for 24 hours with fluvastatin (5 μmol/L) or fluvastatin + mevalonate (100 μmol/L) in the absence or presence of TPA (50 ng/mL). Conditioned media were collected and MMP-9 activity measured by gelatin zymography. Data are mean ± SD of 3 experiments performed in duplicate. Student t test: a indicates $P<0.05$ vs control; b, $P<0.05$ vs fluvastatin alone; c, $P<0.05$ vs TPA alone; and d, $P<0.05$ vs TPA + fluvastatin.

As shown in Figure 4B, this enhancement was dose-dependently blocked due to an interaction of the drug with the protease already secreted into the media, as shown by gelatin gel zymography. None of the tested compounds showed any appreciable effect on MMP-9 activity (data not shown), thus suggesting that fluvastatin did not interfere with the activation of the protease.

To exclude a possible drug toxicity as the reason of its inhibitory effect, MPMs were incubated with fluvastatin (5 to 100 μmol/L) in the absence or presence of TPA (50 ng/mL); then, cell viability was assessed using the dimethylthiazolyl-diphenyltetrazolium bromide assay. Fluvastatin did not cause any appreciable cellular toxicity, even at the highest concentration used (100 μmol/L). In another set of experiments, cells were incubated for 24 hours with medium containing fluvastatin and then for 24 hours with medium alone. As shown in Table 1, withdrawal of the drug restored the capacity of cells to secrete normal amounts of MMP-9. These data further confirm that fluvastatin is not toxic and that its inhibitory effect is reversible.

![Table 1](http://atvb.ahajournals.org/)

**TABLE 1. Reversibility of the Inhibitory Effect of Fluvastatin on MMP-9 Activity**

<table>
<thead>
<tr>
<th>Additions, μmol/L</th>
<th>Treatment</th>
<th>Washout</th>
</tr>
</thead>
<tbody>
<tr>
<td>No addition</td>
<td>1153±108</td>
<td>1139±66</td>
</tr>
<tr>
<td>Fluvastatin, 5</td>
<td>899±38*</td>
<td>1261±15</td>
</tr>
</tbody>
</table>

Cells were incubated for 24 hours with medium alone or containing fluvastatin (5 μmol/L). Media then were collected, and the cells were incubated for 24 hours in the absence of the drug. MMP-9 activity was measured by zymography at both time points. Student t test: *$P<0.05$ vs control (nontreated cells).

To assess whether fluvastatin was effective also in HMs, we performed a new series of experiments. As shown in Figure 4A, the incubation of HMs with increasing concentrations of fluvastatin caused a significant and dose-dependent reduction of MMP-9 activity in the culture medium. At the lowest concentration used (0.1 μmol/L), fluvastatin inhibited MMP-9 activity by 20%, and at the highest (50 μmol/L), by 45% compared with control (Figure 4A). Fluvastatin inhibitory effect was also maintained in the presence of phorbol ester. The addition of TPA alone (50 ng/mL of medium) determined a 2.5-fold increase of MMP-9 activity (Figure 4B). This enhancement was dose-dependently blocked (25% to ≤60% compared with cells treated with TPA alone) by increasing amounts of fluvastatin (0.1 to 50 μmol/L; Figure 4B).

We also performed a Western blot analysis of the media collected from HMs incubated with fluvastatin. As shown in Figure 5, the addition of fluvastatin, 5 and 50 μmol/L, reduced the amount of MMP-9 protein released into the incubation media by 25% and 50%, respectively. The coincubation with exogenous mevalonate blocked the inhibitory effect of fluvastatin (Figure 5).

To confirm the above observation obtained with murine macrophages that the inhibitory effect of fluvastatin was not due to an interaction of the drug with the protease already secreted into the media, we performed a different experiment. HMs were incubated with fluvastatin (5 μmol/L alone or with 100 μmol/L mevalonate) for 24 hours. Media were discarded, and cells were incubated for an additional 4 hours with medium alone. At the end of the second incubation, media were collected and analyzed by zymography. Fluvastatin still maintained its inhibitory effect on MMP-9 activity, and mevalonate prevented this effect (Figure 6A). This reduction in gelatinolytic activity is due to a reduction of the amount of MMP-9 protein released in the incubation media, as shown by Western blot analysis (Figure 6B).

We also measured the amount of MMP-9 protein secreted by HMs with ELISA. As shown in Table 2, the addition of fluvastatin (5 and 50 μmol/L) inhibited the secretion of MMP-9 protein, whereas the coincubation with mevalonate prevented the inhibitory effect.

To determine whether the inhibitory effect we observed was specific to fluvastatin, we used a different HMG-CoA reductase inhibitor simvastatin. Data in Table 3 show that the
incubation of mouse macrophages with increasing concentrations of the latter statin caused an inhibition in MMP-9 activity similar to that observed with fluvastatin.

Finally, we evaluated by Northern blot analysis whether the reduced levels of secreted MMP-9 in fluvastatin-treated HMs could reflect a reduction in MMP-9 gene expression. As shown in Figure 7, Northern blots of HMs treated for 24 hours with 50 μmol/L fluvastatin demonstrated no reduction in the level of MMP-9 gene expression. Instead, an almost 2-fold increase in mRNA levels for MMP-9 was consistently observed. In contrast, essentially no change was observed in the levels of the housekeeping gene G3PDH.

Discussion
In this study, we have demonstrated that the in vitro incubation of mouse macrophages and HMs with fluvastatin or simvastatin, 2 hypolipidemic and antiatherosclerotic agents, reduced the amount of MMP-9 secreted, suggesting that the effect on MMP-9 activity belongs to the statins as a class of drugs. Cells were treated for 24 hours with increasing concentrations of fluvastatin, and the data clearly show that the inhibition of the HMG-CoA reductase enzyme reduces the amount of protease released into the incubation media. This effect is reversible and appears to be mediated through a starvation of mevalonate and its derivatives, because the coincubation of the cells with fluvastatin and mevalonate completely overcame the inhibitory effect of the drug. The experiments show that fluvastatin reduced MMP-9 activity in gelatin zymography and that the effect of the drug was also maintained when MMP-9 production was induced by the coincubation with TPA, a known inducer of MMP gene transcription. TPA induced a 1.5- to 2.5-fold increase in

Figure 4. Fluvastatin inhibits MMP-9 activity in HMs. HMs were incubated for 24 hours with increasing concentrations of fluvastatin in the absence (A) or presence (B) of TPA (50 ng/mL). Conditioned media were collected and MMP-9 activity measured by gelatin zymography. Data are mean ± SD of 3 experiments performed in duplicate. Student t test. A, a indicates \( P < 0.05 \); b, \( P < 0.005 \) vs control (nontreated cells). B, a indicates \( P < 0.01 \) vs control; b, \( P < 0.01 \) vs TPA alone.

Figure 5. Representative Western blot analysis of MMP-9 secretion by HMs and quantitation by densitometry. HMs were incubated for 24 hours with fluvastatin (5 or 50 μmol/L) or fluvastatin (5 μmol/L) plus mevalonate (100 μmol/L). Conditioned media were collected and MMP-9 secretion assessed by Western blot analysis.
MMP-9 activity in mouse macrophages and HMs, respectively. In these conditions, fluvastatin inhibited MMP-9 activity up to 60% compared with the value obtained in cells incubated with TPA alone.

The inhibitory effect of fluvastatin on MMP-9 activity detected by zymography could be the consequence of direct interference of the drug with the activation process of the MMPs after this has been secreted. Our data exclude this hypothesis, because the drug did not have any effect on the activity of MMP-9 already secreted into the growth media. In addition, as evaluated by Western blot analysis and ELISA, fluvastatin reduced the amount of MMP-9 protein released by the cells, suggesting a direct effect on the secretion process.

The reduced levels of MMP-9 detected in the media by ELISA, Western blot analysis, and zymography could also be the result of a fluvastatin-mediated decrease in MMP-9 gene expression. Our data clearly indicate that this is not the case, because mRNA levels actually rose in treated cells. This would suggest a complex mechanism of action of the drug affecting posttranscriptional processes for MMP-9. A more detailed examination of these processes, beyond the scope of this article, will be required to fully understand the mechanism(s) involved.

In addition to TGF-β, corticosteroids, and heparin, several synthetic inhibitors of MMPs have been investigated: viz, tetracyclines, antracyclines, and synthetic peptides. The synthetic inhibitors of MMPs have been investigated: viz, tetracyclines, antracyclines, and synthetic peptides. The therapeutic efficacy of all of these molecules, however, is doubtful. Inhibition of MMP activity has demonstrated a direct effect in reducing tumor cells invasion and angiogenesis. The MMP inhibitor GM 6001 was shown to block SMC migration. The synthetic MMP inhibitor BB94 (Bimatstat) inhibits gelatinases A and B with IC₅₀ values of 4 and 10 nmol/L, respectively, and is able to reduce intimal thickening after arterial injury by decreasing both SMC migration and proliferation. These data support the conclusion that MMPs play a significant role in regulating intimal thickening in injured arteries and therefore in atherogenesis.

Fluvastatin and simvastatin are inhibitors of the HMG-CoA reductase enzyme, a key step in the cholesterol biosynthetic pathway, which synthesizes mevalonate, the precursor of isoprenoids, a class of compounds involved in several cellular processes. The treatment with the inhibitors causes mevalonate starvation inside the cells. This seems to cause the inhibition of MMP-9 secretion, because the coincubation with mevalonate completely overcame the reduction of MMP-9 secretion. Prenylation is a type of stable lipid modification involving covalent addition of either farnesyl or geranylgeranyl isoprenoids to conserved cysteine residues at or near the C-terminus of proteins. Known prenylated proteins include fungal mating factors, nuclear lamins, Ras and Ras-related GTP-binding proteins, protein kinases, and at least 1 viral protein. Prenylation promotes membrane interactions of most of these proteins and plays a major role in

### Table 2: Effect of Fluvastatin on the Secretion of MMP-9 by HMs

<table>
<thead>
<tr>
<th>Additions, μmol/L</th>
<th>Secreted Proteins, ng/μg Cell Protein±SD (MMP-9)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No addition</td>
<td>1.51±0.08</td>
</tr>
<tr>
<td>Fluvastatin, 5</td>
<td>0.88±0.07*</td>
</tr>
<tr>
<td>Fluvastatin, 50</td>
<td>0.63±0.03*</td>
</tr>
<tr>
<td>Fluvastatin, 5+Mevalonate, 100</td>
<td>0.39±0.12</td>
</tr>
</tbody>
</table>

HMs were incubated for 24 hours with medium alone (control) or containing the indicated concentrations of fluvastatin. Conditioned media were collected, and the amount of secreted MMP-9 was measured by ELISA as described in Methods. Data are mean±SD of 2 experiments performed in duplicate. Student t test: *P<0.01 vs control (nontreated cells).

### Table 3: Simvastatin Inhibits MMP-9 Activity in Mouse Macrophages

<table>
<thead>
<tr>
<th>Additions, μmol/L</th>
<th>MMP-9 Activity, OD Units±SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>No addition</td>
<td>1350±120</td>
</tr>
<tr>
<td>Simvastatin, 5</td>
<td>1363±203</td>
</tr>
<tr>
<td>Simvastatin, 10</td>
<td>1078±32*</td>
</tr>
<tr>
<td>Simvastatin, 50</td>
<td>1011±91*</td>
</tr>
<tr>
<td>Dexamethasone, 0.1</td>
<td>13±††</td>
</tr>
</tbody>
</table>

Mouse macrophages were incubated for 24 hours with increasing concentrations of simvastatin or dexamethasone (0.1 μmol/L). Conditioned media were collected, and MMP-9 activity was measured by gelatin zymography. Data are mean±SD of 2 experiments performed in duplicate. Student t-test: *P<0.05; †P<0.01 vs control (nontreated cells).
several protein-protein interactions and in signal transduction.

Prenylated proteins of the Rab subgroup, small Ras-like GTPases in mammalian cells, have an important role in regulating membrane traffic and exocytic and endocytic transport processes. An inhibition of Rab prenylation causes a block in protein secretion, and the Rab3A is deeply involved in regulated secretion in neuronal cells. Therefore, it is conceivable that the inhibition of isoprenoids formation by statins could lead to a reduced MMP-9 secretion by several protein-protein interactions and in signal transduction. 

Preynlated proteins of the Rab subgroup, small Ras-like GTPases in mammalian cells, have an important role in regulating membrane traffic and exocytic and endocytic transport processes. An inhibition of Rab prenylation causes a block in protein secretion, and the Rab3A is deeply involved in regulated secretion in neuronal cells. Therefore, it is conceivable that the inhibition of isoprenoids formation by statins could lead to a reduced MMP-9 secretion by macrophages, by inhibiting factor(s) essential for the secretion process.

Extrapolation of our in vitro results to the in vivo condition is difficult, of course. The final net level of proteinase activity depends on several factors, such as the relative concentrations of active enzymes and specific inhibitors (ie, TIMPs), and further studies are required to assess the in vivo relevance of our observation. Nevertheless, several clinical studies demonstrated the ability of statins to reduce the incidence of coronary heart disease, most probably by increasing the stability of the atherosclerotic plaque rather than by reducing the stenotic occlusion. This effect may involve, in addition to cholesterol reduction, a direct effect of these drugs on the arterial wall. We previously suggested that statins may reduce modified LDL endocytosis and cholesterol accumulation in macrophages. The inhibitory effect of statins on MMP-9 secretion observed in the present study suggests an additional potential mechanism for the stabilizing effect of these drugs on atherosclerotic plaque.

Acknowledgments

This study was supported in part by the National Council for Research (C.N.R.) and by MURST (to R.F.; Italian Government). We thank Laura Mozzarelli for expert preparation of the manuscript.

References


HMG-CoA Reductase Inhibitors Reduce MMP-9 Secretion by Macrophages

doi: 10.1161/01.ATV.18.11.1671
Arteriosclerosis, Thrombosis, and Vascular Biology is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 1998 American Heart Association, Inc. All rights reserved.
Print ISSN: 1079-5642. Online ISSN: 1524-4636

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://atvb.ahajournals.org/content/18/11/1671